Research Article
Characteristics, Risk Factors, and Outcomes in Acute Kidney Injury Patients: A Retrospective Cross-Sectional Study, Palestine
Table 3
Determinants of the association between patient characteristics and need for renal replacement therapy.
| Characteristic | Categories | Renal replacement therapy n (%) | value | Adjusted value | Adjusted OR (95% CI) | Yes | No |
| Complication | Hyperkalemia | 34 (22.8) | 115 (77.2) | 0.01 | 0.435 | 0.610 (0.176–2.112) | No hyperkalemia | 12 (10.9) | 98 (89.1) | Hyperphosphatemia | 20 (27.8) | 52 (72.2) | 0.009 | 0.045 | 0.324 (0.107–0.976) | No hyperphosphatemia | 26 (13.9) | 161 (86.1) | Hypermagnesemia | 13 (19.4) | 54 (80.6) | 0.6 | Not applied | Not applied | No hypermagnesemia | 33 (17.2) | 159 (82.8) | Metabolic acidosis | 12 (66.7) | 6 (33.3) | <0.001 | 0.016 | 0.180 (0.044–0.726) | No metabolic acidosis | 34 (14.1) | 207 (85.9) |
| Stage | Stage 1 | 6 (9.5) | 57 (90.5) | <0.001 | Reference | Stage 2 | 3 (3.9) | 73 (96.1) | 0.149 | 12.85 (0.401–411.41) | Stage 3 | 37 (30.8) | 83 (69.2) | 0.019 | 38.773 (1.836–818.59) |
| Drug during admission | NSAIDS | 17 (14.9) | 97 (85.1) | 0.2 | Not applied | Not applied | No NSAIDs | 29 (20) | 116 (80) | Antibiotic | 27 (17.2) | 130 (82.8) | 0.7 | Not applied | Not applied | No antibiotic | 19 (18.6) | 83 (81.4) | ACE-I/ARBs | 11 (20) | 44 (80.0) | 0.6 | Not applied | Not applied | No ACE-I/ARBs | 35 (17.2) | 169 (82.8) | Diuretic | 30 (23.6) | 98 (76.4) | 0.01 | 0.956 | 1.031 (0.344–3.095) | No diuretic | 16 (12.1) | 116 (87.9) |
| Serum creatinine (mg/dl) (IQR) | 0.5 (0.44–0.66) | <0.001 | <0.001 | 2.216 (1.398–3.514) |
|
|
NSAIDs: nonsteroidal anti-inflammatory drugs, angiotensin-converting enzyme inhibitor/angiotensin receptor blockers, antibiotics (cephalosporin, aminoglycoside, bacitracin, and vancomycin), diuretics (furosemide, serum creatinine = the highest level registered during the same admission). The bold values signify values <0.05.
|